Core Insights - Eli Lilly is well-positioned to attract future investments in India due to its strong scientific base, academic resources, and skilled workforce [1][10] - The company emphasizes the need for improved regulatory frameworks, including data protection and faster clinical trial approvals, to enhance India's competitiveness in attracting high-value research [3][10] - Lilly's performance has been robust, driven by new medicines addressing significant unmet medical needs, with a positive outlook for future growth [7][8] Investment Environment - India is seen as an attractive destination for investments, with recent announcements to increase accredited clinical trial sites being a positive development [2][11] - Regulatory data protection is crucial for the pharmaceutical industry, as it ensures that investments in clinical efficacy and safety data can be recouped [5][11] - The regulatory review process in India currently takes up to one and a half years, which could be streamlined to attract more research investments [3][11] Pricing and Market Dynamics - The pricing of medicines in India is aligned with the country's GDP per capita, ensuring that prices are significantly lower than in markets like Germany or the U.S. [6][11] - The innovative pharmaceutical industry is essential for the existence of generics, highlighting the interdependence between innovative and generic drug markets [6][11] Product Pipeline and Future Outlook - Eli Lilly is expanding its product pipeline, with upcoming launches including Donanemab for Alzheimer's disease in 2026, subject to regulatory approvals [9][11] - The company is also working on an oral GLP-1 and retatrutide, a triple agonist, which has shown significant weight loss results in studies [9][11] - Lilly's focus on R&D continues to drive its growth in various therapeutic areas, including type 2 diabetes, obesity, Alzheimer's disease, and breast cancer [7][11]

Core Insights - New to The Street is a prominent financial media brand that broadcasts weekly on Bloomberg Television and Fox Business, reaching millions of households across the U.S., Latin America, and MENA regions [6] Group 1: Featured Companies - FreeCast (NASDAQ:CAST) is transforming digital media aggregation and streaming access for consumers worldwide [3] - KLED.ai is advancing AI-driven enterprise and data intelligence solutions [3] - Lantern Pharma (NASDAQ:LTRN) is a leader in AI-powered oncology drug development [3] - BlackBarn Restaurant is a premier culinary destination in New York City known for its farm-to-table excellence [3] - Virtuix (NASDAQ:VRTX) specializes in immersive virtual reality technology [4] - NRx Pharmaceuticals (NASDAQ:NRXP) focuses on advanced therapeutics for critical conditions [4] - PetVivo Holdings is involved in veterinary regenerative medicine [4] - DataVault AI (NASDAQ:DVLT) provides data monetization and tokenization infrastructure [4] - Roadzen (NASDAQ:RDZN) offers an AI-powered insurance and mobility platform [4] - Stardust Power (NASDAQ:SDST) is engaged in lithium and energy infrastructure solutions [4] - CISO Global (NASDAQ:CISO) is an enterprise cybersecurity leader [4] - The Sustainable Green Team (OTC:SGTM) focuses on climate and sustainable infrastructure solutions [4] Group 2: Media Reach and Impact - New to The Street has a combined platform reach exceeding 5.1 million subscribers, including 4.44 million on its YouTube channel and over 700,000 on the NewsOut Digital Network [4][5] - The platform utilizes various distribution channels, including LinkedIn, X, Instagram, and Facebook, along with iconic billboard placements in Times Square and NYC's Financial District [4] - New to The Street continues to outperform traditional financial media platforms in terms of reach, engagement, and measurable impact, establishing itself as a dominant force in next-generation financial media [5]

Core Viewpoint - Johnson & Johnson received FDA approval for ICOTYDE, an oral treatment for moderate to severe plaque psoriasis, which is seen as a positive development despite the stock's recent decline [1]. Group 1: Company Overview - Johnson & Johnson develops and sells healthcare products, including pharmaceuticals and medical technologies, with a focus on immunology, oncology, neuroscience, cardiovascular care, and infectious diseases [2]. Group 2: Market Reaction - Despite the positive news regarding FDA approval, the stock finished down 0.35% in a challenging market session, indicating that broader market conditions may have overshadowed the company's announcement [1]. - The current market environment is described as a "terrible, horrible, no good, very bad day," suggesting that such conditions may create buying opportunities for investors in Johnson & Johnson [1].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Ultragenyx Pharmaceutical Inc. during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Ultragenyx common stock between August 3, 2023, and December 26, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by April 6, 2026 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Case Background - The lawsuit alleges that Ultragenyx's defendants provided misleading information regarding the expected results of their Phase III Orbit and Cosmic Studies for setrusumab (UX 143) in treating Osteogenesis Imperfecta [5]. - It is claimed that the defendants made overly positive statements about setrusumab's efficacy while concealing material adverse facts, leading to inflated stock prices for Ultragenyx [6].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Aquestive Therapeutics, Inc. due to alleged violations of federal securities laws related to misleading statements about the company's NDA for Anaphylm [2][5]. Group 1: Legal Investigation and Claims - The law firm is encouraging investors who suffered losses in Aquestive between June 16, 2025, and January 8, 2026, to discuss their legal rights [1]. - A federal securities class action has been filed against Aquestive, with a deadline of May 4, 2026, for investors to seek the role of lead plaintiff [2]. - The complaint alleges that Aquestive and its executives failed to disclose significant deficiencies in the NDA for Anaphylm, particularly regarding human factors in the use of its sublingual film [5]. Group 2: Stock Price Impact - Following the announcement of deficiencies in the NDA by the FDA on January 9, 2026, Aquestive's stock price dropped by $2.30 per share, representing a 37.04% decline, closing at $3.91 per share [6]. Group 3: Firm Background and Outreach - Faruqi & Faruqi, LLP has recovered hundreds of millions of dollars for investors since its founding in 1995 and has offices in multiple states [4]. - The firm is also seeking information from whistleblowers, former employees, and shareholders regarding Aquestive's conduct [8].

Core Insights - The drug discovery process is inefficient, requiring an average of 2,500 compounds and over four years to find one candidate for clinical trials [2][4] - Artificial intelligence (AI) is transforming drug discovery by analyzing large datasets and speeding up the identification of promising compounds [3] Company Summaries Recursion Pharmaceuticals - Recursion Pharmaceuticals has improved the drug discovery process, averaging 330 compounds synthesized in 17 months compared to the industry average [4] - The company utilizes a drug development operating system that integrates robotic labs, large biological datasets, and AI models, with proprietary datasets valued at $213 million from Roche and Genentech [5] - For full-year 2025, Recursion's revenue is projected at $74.7 million, with five clinical programs in progress and a cash runway extending into 2028 [6] - The company has demonstrated clinical proof-of-concept with a 43% median reduction in polyp burden for Familial Adenomatous Polyposis patients [6] Tempus AI - Tempus AI has developed a vast library of clinical and molecular data to enhance precision medicine, focusing on oncology, diagnostics, and genomics [8] - The company reported trailing revenue of $1.27 billion, growing approximately 30% annually, with a strong data engine driven by diagnostics [9] - Tempus is currently unprofitable with a net loss of $245 million, but analysts project nearly 30% annual revenue growth over the next three years [12] Industry Context - The healthcare industry in the U.S. is valued at $4.7 trillion, and advancements in AI could significantly change drug discovery and disease diagnosis [13] - Both Recursion Pharmaceuticals and Tempus AI are positioned to become integral parts of the evolving healthcare infrastructure [13][14]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Inovio Pharmaceuticals, Inc. securities between October 10, 2023, and December 26, 2025, of the April 7, 2026, deadline to become a lead plaintiff in a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Inovio securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court by April 7, 2026, to serve as lead plaintiff, representing other class members [3]. - The lawsuit alleges that defendants made false and misleading statements regarding Inovio's CELLECTRA device manufacturing and the likelihood of submitting the INO-3107 Biologics License Application to the FDA by the second half of 2024 [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been ranked No. 1 for securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions of dollars for investors [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in handling such cases [4].

Core Viewpoint - The Schall Law Firm is investigating potential breaches of fiduciary duty by the board of directors and management of Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) on behalf of its investors [1][2]. Group 1: Investigation Details - The investigation aims to determine if the Verrica board has breached its fiduciary duties to shareholders [2]. - Shareholders are encouraged to participate in the investigation and can contact the Schall Law Firm for more information [2]. Group 2: Firm Background - The Schall Law Firm specializes in securities class action lawsuits and shareholder rights litigation, representing investors globally [3].

Group 1 - X-energy has filed for an initial public offering (IPO) in the United States, aiming to capitalize on increasing investor interest in nuclear power [1] - The company intends to list its Class A common stock on the Nasdaq under the ticker symbol "XE" [1] - Specific details regarding the number of shares to be offered and the price range have not been disclosed [2]

Core Viewpoint - EyePoint Inc has filed a lawsuit against Ocular Therapeutix, alleging the spread of false or misleading information regarding EyePoint's lead experimental eye drug, Duravyu [1][2]. Group 1: Legal Actions - The lawsuit was filed in Middlesex County Superior Court, Massachusetts, accusing Ocular Therapeutix of defamation, commercial disparagement, and violations of consumer protection law [2][3]. - EyePoint is seeking a court order to stop Ocular Therapeutix from making the alleged false statements, demand a public retraction, and claim monetary damages and legal fees [3]. Group 2: Product Development - EyePoint's Duravyu is currently undergoing late-stage studies for wet age-related macular degeneration (wet AMD) and diabetic macular edema, with data for wet AMD expected to be available by mid-2026 [4]. - Ocular Therapeutix's leading drug, Axpaxli, recently met the main goal of a key late-stage trial, demonstrating its effectiveness in helping patients with wet AMD maintain vision compared to Regeneron's Eylea [4].